📰 Rom News
Page 638 - Rom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.
May 5, 2023
Olivia Townsend from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price is unchanged and still at EUR 170. | May 5, 2023
May 5, 2023
In his latest research note, analyst Simon Keller confirms his positive recommendation. The broker Hauck & Aufhauser is keeping its Buy rating. The target price is being increased from EUR 30 to EUR... | May 5, 2023
May 5, 2023
Private bank Berenberg raised its price target for Henkel to 58 euros from 52 euros, but left its rating at Sell. Unexpectedly strong organic growth in the first quarter and lower expected raw... | May 5, 2023
May 5, 2023
In a research note published by Simon Irwin, Credit Suisse advises its customers to buy the stock. The target price is lowered from EUR 46 to EUR 43. | May 5, 2023
May 5, 2023
Analyst Shannon Cross from Credit Suisse research considers the stock attractive and recommends it with a Buy rating. The target price remains set at USD 188. | May 5, 2023
May 5, 2023
Koninklijke Brill N.V. Koninklijke Brill N.V. Below you will find information from the register publication of inside information. The information has... | May 5, 2023
May 5, 2023
UKs FTSE 100 rose on Friday as an uptick in crude prices supported energy stocks and investors digested interest rate hikes from major central banks, while British Airways-owner IAG topped the index... | May 5, 2023
May 5, 2023
In a research note published by Christophe Menard, Deutsche Bank advises its customers to buy the stock. The target price has been raised from EUR 29 to EUR 35. | May 5, 2023
May 5, 2023
In a research note, Deutsche Bank analyst Mitch Collett has maintained his recommendation on the stock with a Neutral rating. The target price is reduced from EUR 61 to EUR 59. | May 5, 2023
May 5, 2023
U.S. bank JPMorgan raised its price target for Morphosys to 12 euros from 11 euros after the biotech companys quarterly results, but left its rating at underweight. Analyst James Gordon lowered his... | May 5, 2023